Myozyme Studies Seek More Data On Pompe

Genzyme, the Cambridge, Mass., biopharmaceutical company that developed Myozyme, will continue to test this laboratory-engineered enzyme, which compensates for missing acid maltase, in people with Pompe disease (acid maltase deficiency).

A new study will test higher and more frequent dosing regimens of Myozyme in 12 patients who are at least 6 months old and have shown less than optimal improvement on the standard Myozyme regimen, which is an intravenous infusion every other week of 20 milligrams per kilogram of body weight.

For more information, contact Deya Corzo, senior medical director at Genzyme, at (800) 745-4447 or (617) 252-7832, or write to medinfo@genzyme.com; and see Myozyme Dose and Dose Interval Study.

The company is also planning a study to evaluate the long-term growth and development of patients with infantile-onset Pompe disease treated with Myozyme before they’re a year old.